Treatment of diarrhea associated with Clostridioides difficile.
Elimination of diarrhea caused by Clostridioides difficile.
Absorption: Minimal systemic absorption.
Distribution: Stays primarily in the GI tract.
Metabolism and Excretion: Mostly transformed via hydrolysis in the GI tract to OP-1118, its active metabolite. Eliminated mostly (>92%) in feces: <1% excreted in urine.
Half-life: Fidaxomicin– 11.7 hr; OP-1118– 11.2 hr.
Use Cautiously in:
GI: GI HEMORRHAGE, nausea, abdominal pain
Hemat: anemia, neutropenia
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
PO (Adults): 200 mg twice daily for 10 days .
PO (Children ≥6 mo and ≥12.5 kg): Tablets– 200 mg twice daily for 10 days (if unable to swallow tablets, use granules for oral suspension).
PO (Children ≥6 mo and 9–<12.5 kg): Granules for oral suspension– 160 mg twice daily for 10 days.
PO (Children ≥6 mo and 7–<9 kg): Granules for oral suspension– 120 mg twice daily for 10 days.
PO (Children ≥6 mo and 4–<7 kg): Granules for oral suspension– 80 mg twice daily for 10 days.
Granules for oral suspension (berry-flavor): 200 mg/5 mL
Tablets: 200 mg
Lab Test Considerations:
May cause ↑ serum alkaline phosphatase, and hepatic enzymes.
Administer twice daily, about 12 hr apart, without regard to food.
Decrease in diarrhea caused by Clostridioides difficile.
Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Complete Product Information.